p. 2733−2733
2476-762X
Vol.17/No.6
p. 2735−2739
2476-762X
Vol.17/No.6
p. 2741−2744
2476-762X
Vol.17/No.6
p. 2741−2744
2476-762X
Vol.17/No.6
p. 2745−2750
2476-762X
Vol.17/No.6
p. 2751−2755
2476-762X
Vol.17/No.6
p. 2757−2760
2476-762X
Vol.17/No.6
36 years old; X2-test=17.794, p-value=0.001), education (primary school; X2-test=18.952, p-value=0.001), marital status (married; X2-test=12.399, p-value=0.002), and income (<5,000 baht; X2-test=27.757, p-value=0.015) were significantly associated with raw fish consumption. This result indicates that the population had risk consumption for liver fluke infection particularly of various cyprinoid fishes that are 2nd intermediate hosts. Therefore, health education is required to improve their behavior.]]>
p. 2761−2765
2476-762X
Vol.17/No.6
p. 2767−2773
2476-762X
Vol.17/No.6
p. 2775−2780
2476-762X
Vol.17/No.6
250 pg/ml) was significantly higher than in the control group (Conclusions: These findings indicate a potential clinical significance of serum MMP13 measurement for early detection and prognostic assessment in ESCC patients.]]>
p. 2781−2785
2476-762X
Vol.17/No.6
p. 2787−2793
2476-762X
Vol.17/No.6
p. 2795−2799
2476-762X
Vol.17/No.6
p. 2801−2804
2476-762X
Vol.17/No.6
p. 2805−2810
2476-762X
Vol.17/No.6
p. 2811−2819
2476-762X
Vol.17/No.6
p. 2811−2819
2476-762X
Vol.17/No.6
p. 2821−2826
2476-762X
Vol.17/No.6
p. 2827−2832
2476-762X
Vol.17/No.6
p. 2833−2839
2476-762X
Vol.17/No.6
p. 2841−2846
2476-762X
Vol.17/No.6
p. 2847−2852
2476-762X
Vol.17/No.6
p. 2853−2856
2476-762X
Vol.17/No.6
p. 2857−2860
2476-762X
Vol.17/No.6
0.05) except laterality and metastasis of the tumor (P values=0.006 and 0.06, respectively). The CYP1B1 polymorphism Val432Leu was not associated with breast cancer in Egypt, but may provide clues for future studies into early detection of the disease.]]>
p. 2861−2866
2476-762X
Vol.17/No.6
0.05) except laterality and metastasis of the tumor (P values0.006 and 0.06, respectively). The CYP1B1 polymorphism Val432Leu was not associated with breast cancer in Egypt, but may provide clues for future studies into early detection of the disease.]]>
p. 2861−2866
2476-762X
Vol.17/No.6
p. 2867−2870
2476-762X
Vol.17/No.6
p. 2871−2876
2476-762X
Vol.17/No.6
p. 2877−2881
2476-762X
Vol.17/No.6
p. 2883−2888
2476-762X
Vol.17/No.6
p. 2889−2894
2476-762X
Vol.17/No.6
p. 2895−2899
2476-762X
Vol.17/No.6
p. 2901−2907
2476-762X
Vol.17/No.6
p. 2909−2916
2476-762X
Vol.17/No.6
p. 2917−2921
2476-762X
Vol.17/No.6
p. 2923−2933
2476-762X
Vol.17/No.6
p. 2935−2940
2476-762X
Vol.17/No.6
50% and ≥1 CPC detected, CPC detection had a higher diagnostic yield. Some 4/41 cancers complied with the criteria for active surveillance, free PSA and the Chun score missed a higher number of significant cancers when compared with CPC detection.
Conclusions: Primary CPC detection outperformed the use of free PSA and the Chun nomagram in predicting clinically significant prostate cancer at repeat prostate biopsy.]]>
p. 2941−2946
2476-762X
Vol.17/No.6
p. 2947−2951
2476-762X
Vol.17/No.6
p. 2953−2957
2476-762X
Vol.17/No.6
p. 2959−2964
2476-762X
Vol.17/No.6
p. 2965−2972
2476-762X
Vol.17/No.6
p. 2973−2977
2476-762X
Vol.17/No.6
p. 2979−2982
2476-762X
Vol.17/No.6
p. 2983−2988
2476-762X
Vol.17/No.6
p. 2989−2993
2476-762X
Vol.17/No.6
50 years was associated with tumors of clinical stage 3 (53.8%), pathological stage 3 (46.2%), pathological grade 3 (45.7%), presence of extracapsular extension (ECE, 48.5%) and lymphovascular invasion (LVI, 64.9%). Locally advanced breast cancers (LABCs) were characterized by pathological stage 3 (96.2%), presence of ECE (100%) and absence of LVI (46.7%) as compared to early breast cancers (EBCs) which had higher incidence of lower stage tumors (100%), absence of ECE (82%) and presence of LVI (91.9%; p-value Conclusions: TNBCs are aggressive tumors which show poor long term survival. Patients with TNBC benefit from chemotherapy, thus better and less toxic treatment options are needed. Identification of newer targets and development of targeted therapies are the need of the hour.]]>
p. 2995−2999
2476-762X
Vol.17/No.6
7 years). We extracted DNA from Formalin-Fixed Paraffin-Embedded (FFPE) samples and examined chromosomal loci and frequencies of CNVs using Taqman copy number assays.
Results: CNV frequently occurred at 3p, 9p, and 13q loci in progressing dysplasia. Our results also indicate that CNV at multiple loci–in contrast to single locus occurrences–is characteristic of progressing dysplasia.
Conclusions: This study suggests that genetic abnormalities of the true precancer demonstrate the progression risk which cannot be delineated by current histopathologic diagnosis.]]>
p. 3001−3006
2476-762X
Vol.17/No.6
p. 3007−3013
2476-762X
Vol.17/No.6
T and -579 G>T Polymorphisms and Risk of Gastric and Colorectal Cancer: a Meta-analysis]]>
T and -579 G>T polymorphisms with gastric cancer (GC) and colorectal cancer (CRC) susceptibility; however, the findings are inconsistent prompting the present meta-analysis.
Materials and Methods: Related studies were identified from PubMed, Google scholar, and SID until 10 October 2015. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations.
Results: Eleven studies were included based on the search criteria for CRC and GC related to the DNMT3B 149 C>T (3,353 cases and 4,936 controls) and DNMT3B 579 G>T (1,387 cases and 2,064 controls) polymorphisms. There was no significant association overall between DNMT3B -149 and 579 polymorphisms and the risk of cancer. In the stratified analysis by cancer type, DNMT3B 579G>T polymorphism was associated with the risk of CRC and GC. While the DNMT3B -149C/T polymorphism was related with a significantly increased risk of CRC in two tested models, dominant (GG+GT vs. TT: OR 0.51, 95 % CI 0.38-0.69; P = 0.00, Pheterogeneity=0.69, I2= 0 %) and heterozygote (GT vs. TT: OR 0.50, 95 % CI 0.37-0.69; P=0.00, Pheterogeneity=0.41, I2= 0 %), no evidence of any association with GC risk was observed as in the pooled analyses.
Conclusions: More studies are needed to assess associations of DNMT3B -149C/T and DNMT3B 579G>T polymorphisms with cancer in different ethnicities with large population sizes to generate comprehensive conclusions]]>
p. 3015−3020
2476-762X
Vol.17/No.6
p. 3021−3023
2476-762X
Vol.17/No.6